CG Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	257.07	8.27	88.14	53.61
Short-Term Investments	484.93	179.41	55.34	-
Cash & Short-Term Investments	742	187.67	143.48	53.61
Cash Growth	295.37%	30.80%	167.65%	-
Other Receivables	0.78	0.09	0.3	0
Receivables	0.78	0.09	0.3	0
Prepaid Expenses	11.43	6.36	3.42	4.8
Total Current Assets	754.21	194.12	147.21	58.41
Property, Plant & Equipment	0.49	0.49	0.51	0.2
Long-Term Deferred Charges	-	4.67	-	-
Other Long-Term Assets	0.09	0.02	0.03	0.09
Total Assets	754.8	199.3	147.75	58.69
Accounts Payable	6.52	3.24	0.99	1
Accrued Expenses	14.23	9.68	5.12	1.89
Current Portion of Long-Term Debt	-	-	8.97	2.94
Current Portion of Leases	0.19	0.22	0.19	0.07
Other Current Liabilities	0.44	1.12	0.17	0.07
Total Current Liabilities	21.37	14.25	15.43	5.98
Long-Term Debt	-	-	6.53	12.06
Long-Term Leases	0.05	0.24	0.26	0.05
Other Long-Term Liabilities	-	0.01	0.35	0.35
Total Liabilities	21.42	14.51	22.57	18.44
Common Stock	0.01	-	-	0
Additional Paid-In Capital	951.35	6.84	3.64	3.27
Retained Earnings	-217.98	-129.94	-81.34	-45.89
Total Common Equity	733.38	-123.1	-77.69	-42.62
Shareholders' Equity	733.38	184.79	125.18	40.25
Total Liabilities & Equity	754.8	199.3	147.75	58.69
Total Debt	0.24	0.46	15.94	15.13
Net Cash (Debt)	741.76	187.21	127.54	38.48
Net Cash Growth	296.21%	46.79%	231.45%	-
Net Cash Per Share	11.87	43.23	34.09	10.54
Filing Date Shares Outstanding	76.22	66.64	3.84	3.65
Total Common Shares Outstanding	76.15	5.22	3.84	3.65
Working Capital	732.84	179.87	131.78	52.43
Book Value Per Share	9.63	-23.57	-20.22	-11.67
Tangible Book Value	733.38	-123.1	-77.69	-42.62
Tangible Book Value Per Share	9.63	-23.57	-20.22	-11.67

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q